Bolt Biotherapeutics to present preclinical data on BDC-3042

Bolt Biotherapeutics announced that it will be presenting a poster with new preclinical data on BDC-3042, a Dectin-2 targeting agonistic antibody, at the 2022 Society for Immunotherapy of Cancer 37th Annual Meeting. The conference is being held both virtually and at the Boston Convention and Exhibition Center in Boston, Mass. from Nov. 8-12. Key Findings from the Study: Tumor-associated macrophages generally support tumor progression by suppressing anti-tumor immune responses. Dectin-2 is expressed by TAMs and agonism of Dectin-2 on TAMs has been shown to drive potent anti-tumor immunity in preclinical animal models. BDC-3042 is an agonistic, Dectin-2-targeted antibody designed to activate TAMs and mediate anti-tumor efficacy, offering a novel approach for macrophage-directed immunotherapy. BDC-3042 is designed to reprogram immunosuppressive TAMs into immunostimulatory cells that drive anti-tumor immunity; BDC-3042 selectively binds to Dectin-2-expressing macrophages and induces an array of pro-inflammatory cytokines, chemokines, and antigen presentation molecules; BDC-3042 exhibits minimal binding to and activation of peripheral leukocytes; BDC-3042 repolarizes TAMs toward an immunostimulatory phenotype and mediates anti-tumor activity in tumor-bearing humanized mice